What You Should Know:
Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior secured loan facility from funds managed by K2 HealthVentures.
Elevation plans to use the funding from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the
Read More
Precision Oncology
Syapse and Pierian Partner to Power Precision Oncology
What You Should Know:
- Syapse, a real-world evidence company is teaming up with Pierian®, a provider of advanced clinical genomics technology on a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida.
- The collaboration combines Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer, Pierian’s leading-edge clinical genomics workflow, and precision medicine services that provide the most relevant
Read More
HealthQuest Capital Closes $675M for Fund IV to Invest in Transformational Healthcare Companies
What You Should Know:
- HealthQuest Capital, a sector specialist capital firm focused on companies optimizing value in healthcare, today announced the close of HealthQuest Partners IV, L.P., at its hard cap of $675M .
- The oversubscribed fund will enable HealthQuest to continue to invest in growth-stage companies that are revolutionizing the healthcare industry.
Providing Growth Capital to Companies Transforming Healthcare
Founded in 2013 by Garheng Kong, a physician, scientist, and
Read More
OncoHost Raises $35M for AI-Powered Precision Oncology Platform
What You Should Know:
- OncoHost, an AI-powered precision oncology platform, today announced a $35M Series C funding round led by ALIVE Israel HealthTech VC, as well as other prominent investors. Additional investors included leading Israeli financial firm Leumi Partners, Israel’s largest pension fund Menora Mivtachim, OurCrowd and other existing investors.
- The funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial as well as support its upcoming
Read More
Mayo Clinic Partners with VUNO to Develop AI-Driven Precision Oncology Solutions
What You Should Know:
- Mayo Clinic has signed a research agreement with VUNO, a global medical artificial intelligence (AI) company to develop advanced AI-driven precision oncology solutions to deliver precision oncology care.
- Through this research agreement, VUNO will establish a collaboration with Mayo Clinic to develop innovative AI and machine learning solutions for more precise diagnosis, prognosis and treatment stratification in cancer.
- This collaborative agreement combines
Read More
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity
Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France
Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More
Verily & Lumea Partner to Leverage AI in Prostate Cancer Diagnoses
What You Should Know:
- Verily and Lumea today announced a strategic partnership to develop products that can diagnose, prognose, and guide prostate cancer therapy selection with improved objectivity and efficiency.
- Lumea’s integrated digital pathology solution will validate Verily’s AI method for improving cancer detection and grading in partnership with Google Health.
Partnership Goals
The Verily-Lumea collaboration will utilize Lumea’s digital pathology platform
Read More
Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer.
- This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate Real-World Evidence in Breast Cancer
As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network
Read More
NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M
What You Should Know:
- NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35 million in cash on hand and $30 million in NeoGenomics common stock and is expected to close in April 2021.
- Trapelo Health offers a first-of-its-kind, interoperable, decision-support
Read More
Why Cancer Registries are Part of America’s Fight for Racial Equality
According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more likely to die during an encounter with police than white males. For some, those figures are staggering. For many others, they are reminders of the racial disparities that have existed for far too long in this country.
So, in 2020, when recent events have brought racial injustice back into the national
Read More
